April 26, 2010 (Vienna, Austria) — In the largest study of its kind to date, about one third of patients infected with hepatitis C virus (HCV) who underwent transplants and were treated with ...

To earn CME related to this news article, click here. March 12, 2009 — Schering-Plough Corporation announced that the US Food and Drug Administration (FDA) has approved an expanded indication for ...

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...

Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text component.

Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice ...

TAIPEI--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new ...

The combination of bulevirtide plus peginterferon alfa-2a is superior to bulevirtide monotherapy for achieving undetectable hepatitis D virus (HDV) RNA level at 24 weeks after the end of treatment in ...

ROCKVILLE, Maryland – November 5, 2007 – Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final quality-of-life results from a Phase 2b clinical trial of the investigational drug, ...

Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...